Which has preferable earnings & valuation, SIBN or TMDX?

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.40 -$18.90M -$0.39 N/A TransMedics Group $605.49M 4.33 $190.29M $4.40 17.23

Which has better valuation & earnings, WRBY or SIBN?

Warby Parker has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Warby Parker $871.91M 3.09 $1.64M $0.02 1,258.25 SiBone $200.93M 3.40 -$18.90M -$0.39 N/A

Is WRBY or SIBN more profitable?

Warby Parker has a net margin of 0.15% compared to SiBone's net margin of -8.10%. Warby Parker's return on equity of 2.30% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets Warby Parker 0.15% 2.30% 1.18% SiBone -8.10% -9.56% -7.06%

Is ESTA or SIBN more profitable?

SiBone has a net margin of -8.10% compared to Establishment Labs' net margin of -19.05%. SiBone's return on equity of -9.56% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Establishment Labs -19.05% -218.77% -12.31% SiBone -8.10% -9.56% -7.06%

Which has preferable valuation & earnings, AXGN or SIBN?

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.25 -$15.70M -$0.64 N/A SiBone $200.93M 3.40 -$18.90M -$0.39 N/A

Is AXGN or SIBN more profitable?

SiBone has a net margin of -8.10% compared to AxoGen's net margin of -13.21%. SiBone's return on equity of -9.56% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% SiBone -8.10% -9.56% -7.06%

Which has better earnings & valuation, LMAT or SIBN?

LeMaitre Vascular has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $249.60M 8.55 $57.73M $2.71 34.46 SiBone $200.93M 3.40 -$18.90M -$0.39 N/A

SiBone (SIBN) Competitors

$15.41 +0.29 (+1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$15.40 -0.01 (-0.03%)

As of 05:26 PM Eastern

Compare

SIBN vs. TMDX, WRBY, ESTA, AXGN, and LMAT

Should you buy SiBone stock or one of its competitors? MarketBeat compares SiBone with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SiBone include TransMedics Group (TMDX), Warby Parker (WRBY), Establishment Labs (ESTA), AxoGen (AXGN), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.

How does SiBone compare to TransMedics Group?

SiBone (NASDAQ:SIBN) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

TransMedics Group has a net margin of 27.04% compared to SiBone's net margin of -8.10%. TransMedics Group's return on equity of 22.38% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
TransMedics Group	27.04%	22.38%	8.46%

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.40	-$18.90M	-$0.39	N/A
TransMedics Group	$605.49M	4.33	$190.29M	$4.40	17.23

SiBone currently has a consensus target price of $23.00, indicating a potential upside of 49.25%. TransMedics Group has a consensus target price of $134.00, indicating a potential upside of 76.73%. Given TransMedics Group's higher probable upside, analysts clearly believe TransMedics Group is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

In the previous week, TransMedics Group had 3 more articles in the media than SiBone. MarketBeat recorded 3 mentions for TransMedics Group and 0 mentions for SiBone. SiBone's average media sentiment score of 0.60 beat TransMedics Group's score of 0.56 indicating that SiBone is being referred to more favorably in the media.

Company	Overall Sentiment
SiBone	Positive
TransMedics Group	Positive

SiBone has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

98.1% of SiBone shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 3.9% of SiBone shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

TransMedics Group beats SiBone on 13 of the 15 factors compared between the two stocks.

How does SiBone compare to Warby Parker?

Warby Parker (NYSE:WRBY) and SiBone (NASDAQ:SIBN) are both medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Warby Parker currently has a consensus price target of $29.50, indicating a potential upside of 17.23%. SiBone has a consensus price target of $23.00, indicating a potential upside of 49.25%. Given SiBone's stronger consensus rating and higher possible upside, analysts plainly believe SiBone is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Warby Parker has a net margin of 0.15% compared to SiBone's net margin of -8.10%. Warby Parker's return on equity of 2.30% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Warby Parker	0.15%	2.30%	1.18%
SiBone	-8.10%	-9.56%	-7.06%

In the previous week, Warby Parker had 7 more articles in the media than SiBone. MarketBeat recorded 7 mentions for Warby Parker and 0 mentions for SiBone. SiBone's average media sentiment score of 0.60 beat Warby Parker's score of 0.33 indicating that SiBone is being referred to more favorably in the news media.

Company	Overall Sentiment
Warby Parker	Neutral
SiBone	Positive

93.2% of Warby Parker shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 16.8% of Warby Parker shares are held by company insiders. Comparatively, 3.9% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Warby Parker has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Warby Parker	$871.91M	3.09	$1.64M	$0.02	1,258.25
SiBone	$200.93M	3.40	-$18.90M	-$0.39	N/A

Warby Parker has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Summary

Warby Parker beats SiBone on 11 of the 16 factors compared between the two stocks.

How does SiBone compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by company insiders. Comparatively, 3.9% of SiBone shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Establishment Labs currently has a consensus target price of $87.14, suggesting a potential upside of 5.54%. SiBone has a consensus target price of $23.00, suggesting a potential upside of 49.25%. Given SiBone's stronger consensus rating and higher possible upside, analysts plainly believe SiBone is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Establishment Labs had 3 more articles in the media than SiBone. MarketBeat recorded 3 mentions for Establishment Labs and 0 mentions for SiBone. Establishment Labs' average media sentiment score of 0.94 beat SiBone's score of 0.60 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Establishment Labs	Positive
SiBone	Positive

SiBone has a net margin of -8.10% compared to Establishment Labs' net margin of -19.05%. SiBone's return on equity of -9.56% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
SiBone	-8.10%	-9.56%	-7.06%

Establishment Labs has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

SiBone has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	11.51	-$51.06M	-$1.49	N/A
SiBone	$200.93M	3.40	-$18.90M	-$0.39	N/A

Summary

SiBone beats Establishment Labs on 9 of the 16 factors compared between the two stocks.

How does SiBone compare to AxoGen?

AxoGen (NASDAQ:AXGN) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.25	-$15.70M	-$0.64	N/A
SiBone	$200.93M	3.40	-$18.90M	-$0.39	N/A

In the previous week, AxoGen had 1 more articles in the media than SiBone. MarketBeat recorded 1 mentions for AxoGen and 0 mentions for SiBone. AxoGen's average media sentiment score of 1.84 beat SiBone's score of 0.60 indicating that AxoGen is being referred to more favorably in the media.

Company	Overall Sentiment
AxoGen	Very Positive
SiBone	Positive

SiBone has a net margin of -8.10% compared to AxoGen's net margin of -13.21%. SiBone's return on equity of -9.56% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
SiBone	-8.10%	-9.56%	-7.06%

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 3.9% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AxoGen has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

AxoGen presently has a consensus target price of $46.50, suggesting a potential upside of 7.14%. SiBone has a consensus target price of $23.00, suggesting a potential upside of 49.25%. Given SiBone's higher probable upside, analysts clearly believe SiBone is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

AxoGen beats SiBone on 9 of the 16 factors compared between the two stocks.

How does SiBone compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, LeMaitre Vascular had 3 more articles in the media than SiBone. MarketBeat recorded 3 mentions for LeMaitre Vascular and 0 mentions for SiBone. LeMaitre Vascular's average media sentiment score of 1.44 beat SiBone's score of 0.60 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Overall Sentiment
LeMaitre Vascular	Positive
SiBone	Positive

LeMaitre Vascular has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.55	$57.73M	$2.71	34.46
SiBone	$200.93M	3.40	-$18.90M	-$0.39	N/A

LeMaitre Vascular has a net margin of 24.35% compared to SiBone's net margin of -8.10%. LeMaitre Vascular's return on equity of 15.36% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
SiBone	-8.10%	-9.56%	-7.06%

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 3.9% of SiBone shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LeMaitre Vascular has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, SiBone has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

LeMaitre Vascular currently has a consensus price target of $112.60, indicating a potential upside of 20.57%. SiBone has a consensus price target of $23.00, indicating a potential upside of 49.25%. Given SiBone's higher probable upside, analysts clearly believe SiBone is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

LeMaitre Vascular beats SiBone on 13 of the 17 factors compared between the two stocks.

Get SiBone News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIBN vs. The Competition

Export

Metric	SiBone	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$683.43M	$7.02B	$6.45B	$12.20B
Dividend Yield	N/A	1.21%	2.66%	5.66%
P/E Ratio	-39.51	47.67	23.92	24.34
Price / Sales	3.40	73.64	517.93	135.34
Price / Cash	N/A	25.59	27.48	37.92
Price / Book	3.77	7.03	10.50	6.70
Net Income	-$18.90M	$159.20M	$3.56B	$337.21M
7 Day Performance	-0.77%	-1.92%	0.19%	1.78%
1 Month Performance	8.83%	6.95%	1.53%	3.65%
1 Year Performance	-14.05%	2.51%	24.25%	28.22%

SiBone Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIBN SiBone	2.1545 of 5 stars	$15.41 +1.9%	$23.00 +49.3%	-13.2%	$683.43M	$200.93M	N/A	350
TMDX TransMedics Group	4.4095 of 5 stars	$72.46 +1.8%	$134.00 +84.9%	-47.2%	$2.50B	$605.49M	16.46	210	Options Volume
WRBY Warby Parker	3.555 of 5 stars	$22.77 -3.2%	$29.50 +29.6%	+19.7%	$2.44B	$871.91M	1,137.57	4,036
ESTA Establishment Labs	1.6571 of 5 stars	$77.62 +3.7%	$87.14 +12.3%	+124.9%	$2.29B	$211.08M	N/A	1,004	News Coverage Positive News
AXGN AxoGen	1.9072 of 5 stars	$41.62 +0.4%	$46.50 +11.7%	+348.6%	$2.21B	$225.21M	N/A	450

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIBN) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SiBone (SIBN) Competitors

SIBN vs. TMDX, WRBY, ESTA, AXGN, and LMAT

How does SiBone compare to TransMedics Group?

Summary

How does SiBone compare to Warby Parker?

Summary

How does SiBone compare to Establishment Labs?

Summary

How does SiBone compare to AxoGen?

Summary

How does SiBone compare to LeMaitre Vascular?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SiBone (SIBN) Competitors

SIBN vs. TMDX, WRBY, ESTA, AXGN, and LMAT

How does SiBone compare to TransMedics Group?

Is SIBN or TMDX more profitable?

Which has preferable earnings & valuation, SIBN or TMDX?

Do analysts prefer SIBN or TMDX?

Does the media refer more to SIBN or TMDX?

Which has more volatility and risk, SIBN or TMDX?

Do institutionals and insiders have more ownership in SIBN or TMDX?

Summary

How does SiBone compare to Warby Parker?

Do analysts rate WRBY or SIBN?

Is WRBY or SIBN more profitable?

Does the media prefer WRBY or SIBN?

Do institutionals and insiders hold more shares of WRBY or SIBN?

Which has better valuation & earnings, WRBY or SIBN?

Which has more risk and volatility, WRBY or SIBN?

Summary

How does SiBone compare to Establishment Labs?

Do insiders & institutionals hold more shares of ESTA or SIBN?

Do analysts recommend ESTA or SIBN?

Does the media prefer ESTA or SIBN?

Is ESTA or SIBN more profitable?

Which has more risk & volatility, ESTA or SIBN?

Which has stronger earnings & valuation, ESTA or SIBN?

Summary

How does SiBone compare to AxoGen?

Which has preferable valuation & earnings, AXGN or SIBN?

Does the media prefer AXGN or SIBN?

Is AXGN or SIBN more profitable?

Do insiders & institutionals have more ownership in AXGN or SIBN?

Which has more volatility and risk, AXGN or SIBN?

Do analysts prefer AXGN or SIBN?

Summary

How does SiBone compare to LeMaitre Vascular?

Does the media prefer LMAT or SIBN?

Which has better earnings & valuation, LMAT or SIBN?

Is LMAT or SIBN more profitable?

Do insiders & institutionals believe in LMAT or SIBN?

Which has more volatility & risk, LMAT or SIBN?

Do analysts recommend LMAT or SIBN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools